Vermillion secures $17.6M to expand its push for ovarian cancer Dx

Vermillion ($VRML) pulled in $17.6 million through the sale of warrants, completing a $31 million equity financing first disclosed in May. The Austin, TX, diagnostics outfit said that Oracle Investment Management, Jack Schuler, Matthew Strobeck and other investors exercised their warrants in the transaction, purchasing 12.1 million shares of common stock at $1.46 per share. The funding will help the company boost sales and reimbursement efforts for Ova1, its pre-surgery algorithmic blood test designed to screen for ovarian cancer. Item

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

A COVID-19 antibody diagnostic developed through a joint venture between Mount Sinai Health System and RenalytixAI has been authorized by the FDA.

Researchers at Northwestern University have trained an AI algorithm to automatically detect the signs of COVID-19 on a basic X-ray of the lungs.

Hand-held ultrasound developer Butterfly Network is going public through a $1.5 billion acquisition deal backed by Glenview Capital.